Search Results

You are looking at 1 - 10 of 22 items for :

  • pharmacokinetics x
  • Biochemistry x
Clear All
Open access

Bojana Golubović, Katarina Vučićević, Dragana Radivojević, Sandra Vezmar Kovačević, Milica Prostran and Branislava Miljković

Introduction Effective immunosuppression plays a crucial role in the successful post-transplantation period. Sirolimus, immunosuppressive which inhibits the cellular response to IL-2 and T-cell proliferation, is approved for the prevention of organ rejection in kidney transplant patients ( 1 , 2 , 3 , 4 ). Sirolimus is characterized by highly variable absorption and elimination which result in substantial blood concentrations differences among patients receiving the same doses ( 5 ). Due to wide intra- and inter-individual pharmacokinetic variability and

Open access

Sylwia Borys, Ronza Khozmi, Wiesława Kranc, Artur Bryja, Michal Jeseta and Bartosz Kempisty

. Prozdrowotne właściwości resweratrolu, Nauka Technologia Jakość 2011; 5 (78): 5-15. [21] Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms, Curr. Med. Chem. 2013; 20 (36): 4640-5. [22] Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in Sprague-dawley rats: the impacts of aqeous solubility, dose escalation, food and repeated dosing on oral bioavailability, J. Pharm. Sci. 2011; 100 (10): 4491-500. [23] Liu Yin MY, Wy X, Zeng M, Zhao Q

Open access

Aleksandra Catić-Đorđević, Tatjana Cvetković, Nikola Stefanović and Radmila Veličković-Radovanović

Initial Immunosuppression Regimen: A National Study. Transpl Int 2016; 29: 1226–36. 9. Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol 2014; 31: 22–32. 10. Brunkhorst LC, Fichtner A, Höcker B, Burmeister G, Ahlenstiel-Grunow T, Krupka K, et al. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. PLoS One 2015; 10: e0135439

Open access

Sachin Kokil and Manish Bhatia

: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916. Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-90. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and

Open access

Sachin Kokil and Manish Bhatia

References Deeks SG, Bardicht CP, Lietman PS, Hwang F, Cundy KC, Rooney JF, et al. Safety, pharmacokinetics and anti-retroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42: 2380-4. Shaw JP, Sueoka CM, Oliyai R, Lee WA, Arimilli KM, Kim CU, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-phosphonomethoxypropyl] adenine (PMPA) in dogs. Pharm

Open access

Cristiano Ialongo, Alessia Francesca Mozzi and Sergio Bernardini

-8. 4. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548-54. 5. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen- related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow

Open access

Nikola Z. Stefanović, Tatjana P. Cvetković, Radmila M. Veličković-Radovanović, Tatjana M. Jevtović-Stoimenov, Predrag M. Vlahović, Ivana R. Stojanović and Dušica D. Pavlović

References 1. Nafar M, Sahraei Z, Salamzadeh J, Samavat S, Vaziri N. Oxidative stress in kidney transplantation: causes, consequences, and potential treatment. Iran J Kidney Dis 2011; 5: 357–72. 2. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006; 112: 184–98. 3. Veličković-Radovanović R, Paunović G, Mikov M, Đorđević V, Stojanović M, Catić-Đorđević A, et al. Clinical pharmacokinetics of tacrolimus after the first oral administration in renal

Open access

Snežana Jovičić, Svetlana Ignjatović and Nada Majkić-Singh

LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endo - genous synthesis. J Clin Invest 1993; 91: 2552-5. 9. Masuda S, Byford V, Arabian A, Sakai Y, Demay MB, St- Arnaud E, et al. Altered pharmacokinetics of 1,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase ( Cyp24a1 ) null mouse. Endocrinology 2005; 146(2): 825-34. 10. Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park HW. Structural analysis of CYP2R1 in complex with vitamin D3. J

Open access

Tatjana Vujić, Snežana Uletilović, Jelica Predojević-Samardžić, Biljana Davidović-Plavšić, Svjetlana Stoisavljević-Šatara and Živko Saničanin

. Kidney Int 2001; 60: 804-17. Alper AB. Nephritis, interstitial. Kidney Int 2006; 69: 213-17. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009; 26: 2039-54. Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure and regulation of the cloned organic anion transporters. Xenobiotica 2008; 38: 889-935. Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS 2009; 11: 250

Open access

Dragana Bačković, Svetlana Ignjatović, Ljiljana Rakićević, Jelena Kusić-Tišma, Dragica Radojković, Branko Čalija, Evgenija Strugarević, Đorđe Radak and Mirjana Kovach

-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic Determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75. 10. Varenhorst C, James S, Erlinge D, Brandt JT, Braun OÖ, Man M, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009; 30: 1744-52. 11. Erlinge D, James S, Duvvuru S, Jakubowski JA, Wagner H, Varenhorst C, et al. Clopidogrel metaboliser